The Impact of Antibiotics MIC Value on the Efficacy of Treatment Regimens for Helicobacter Pylori Infection.
NCT03583476 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1821
Last updated 2018-07-11
Summary
Clarithromycin (CLA)、amoxicillin (AMO)、metronidazole (MET)、levofloxacin (LEV) and tetracycline (TET) are commonly used antibiotics for Helicobacter pylori (Hp) therapy. However, the efficacy of treatment for Helicobacter pylori infection has decreased due to increasing resistance to CLA, MET and LEV. Studies had reported that beside antibiotics resistance, other factors such as age, sex, underlying disease, etc. may also affect the treatment efficacy. In some cases, when the MIC values were beyond the breakpoint, H. pylori strains with lower MIC value had better eradication than the ones with higher MIC value. However, few study investigated the relationship between MIC values and treatment outcome.
The investigators aimed to analyze the impact of influencing factors, especially minimal inhibitory concentration (MIC) value, on the efficacy of different treatment regimens.
Conditions
- Helicobacter Pylori Infection
Interventions
- DRUG
-
Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole
Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.
Sponsors & Collaborators
-
National Taiwan University Hospital
lead OTHER
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-04-01
- Primary Completion
- 2018-12-31
- Completion
- 2018-12-31
Countries
- Taiwan
Study Locations
More Related Trials
-
Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment
NCT03139253 ·Status: UNKNOWN ·Phase: PHASE4
-
Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.
NCT04107194 ·Status: UNKNOWN ·Phase: PHASE3
-
Intraluminal Therapy for Helicobacter Pylori Infection
NCT03124420 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy
NCT03383003 ·Status: COMPLETED ·Phase: NA
-
Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication
NCT01163435 ·Status: COMPLETED ·Phase: PHASE4
-
Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication
NCT00816140 ·Status: COMPLETED ·Phase: PHASE4
-
Intraluminal Clarithromycin Powder Monotherapy for Helicobacter Pylori Infection
NCT03516669 ·Status: COMPLETED ·Phase: PHASE4
-
Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.
NCT03571230 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection
NCT05126121 ·Status: UNKNOWN ·Phase: NA
-
Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment
NCT02988089 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication
NCT07333001 ·Status: COMPLETED
-
Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection
NCT03521726 ·Status: COMPLETED ·Phase: PHASE4
-
Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients
NCT05023577 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection
NCT05133193 ·Status: UNKNOWN ·Phase: NA
-
Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy
NCT01572597 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection
NCT04991584 ·Status: UNKNOWN ·Phase: NA
-
Comparison Between Ten Days Sequential Treatment and Traditional Three Combined Treatment of Helicobacter Pylori
NCT01573975 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology
NCT05742568 ·Status: COMPLETED ·Phase: PHASE4
-
Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication
NCT02596620 ·Status: COMPLETED ·Phase: NA
-
Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection
NCT03616405 ·Status: UNKNOWN ·Phase: PHASE4
-
A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection
NCT02689583 ·Status: UNKNOWN ·Phase: NA
-
Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori
NCT01575899 ·Status: TERMINATED ·Phase: PHASE4
-
Sequential Therapy Versus Quadruple Therapy as Second Line Treatment After Failure of the Standard Triple Therapy for H Pylori Infection
NCT01481844 ·Status: COMPLETED ·Phase: PHASE3
-
Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori Infection
NCT03565484 ·Status: UNKNOWN ·Phase: PHASE4
-
A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection
NCT03658733 ·Status: UNKNOWN ·Phase: PHASE4